Association Between Hemophilia Joint Health Score and Quality of Life Using Results from the XTEND-1 Efanesoctocog Alfa Phase 3 Trial

Oral presentation is available to registered attendees only via the ASH annual meeting virtual platform, as per congress regulations.

Session Name: 322. Hemophilia A and B: Clinical and Epidemiological: Impact of Novel Therapies on Outcomes, Including Long-Term 

Session Date: Monday, December 9, 2024

Session Time: 10:30 AM - 12:00 PM

Presentation Time: 11:30 AM

Study funded by Sobi and Sanofi.

Link to published abstract